A small proof-of-concept phase IIa study published in The Lancet has demonstrated successful treatment in patients on a 6-week course of direct-acting antivirals (DAAs). Patients with hepatitis C (n = 60) were assigned to one of three groups: a 12-week course of sofosbuvir and ledipasvir; a 6 week-course of sofosbuvir, ledipasvir and GS-9669; or a 6-week course of sofosbuvir, ledipasvir and GS-9451. Dual DAA therapy resulted in a 100% SVR12. The addition of GS-9669 or GS-9451 gave a 95% SVR12. All patients completed the treatment and the majority of adverse events were mild.
References
Kohli, A. et al. Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study. Lancet 10.1016/S0140-6736(14)61228-9
Rights and permissions
About this article
Cite this article
High HCV cure-rate on a 6 week course of DAAs. Nat Rev Gastroenterol Hepatol 12, 123 (2015). https://doi.org/10.1038/nrgastro.2015.17
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2015.17
